Macaca mulatta
This Old World monkey species is native to parts of Asia and is known for its adaptability, social intelligence, and genetic similarity to humans.
Macaca mulatta has been extensively studied in fields such as neuroscience, immunology, and developmental biology, contributing to our understanding of human health and disease.
Researchers can optimize their Macaca mulatta studies with PubCompare.ai, an AI-powered tool that helps locate the best protocols from literature, preprints, and patents.
With intelligent comparisons, PubCompare.ai can enhance reproducibility and accuracy in Macaca mulatta research, taking your studies to the next lavel.
Most cited protocols related to «Macaca mulatta»
Rich information for gene expression is provided in AnimalTFDB 2.0. We downloaded the human gene expression data of cancers, tissues and cell lines from TCGA (
Most recents protocols related to «Macaca mulatta»
Example 2
Immunization with Recombinant Extracellular Domain of CD22.
Twelve UniRat animals (6 HC27, 6 HC28) were immunized with recombinant human CD22 protein. The animals were immunized according to standard protocol using a Titermax/Alhydrogel adjuvant. Recombinant extracellular domain of CD22 was purchased from R&D Systems and was diluted with sterile saline and combined with adjuvant. The immunogen was combined with Titermax and Alhydrogel adjuvants. The first immunization (priming) with immunogen in Titermax was administered in the left and right legs. Subsequent boosting immunizations were done in the presence of Alhydrogel and three days before harvest boosts were performed with immunogens in PBS. Serum was collected from rats at the final bleed to determine serum titers.
Serum Titer Results
Serum titer summary information is shown in
Example 7
Use in Patients for Treating Solid Tumours
Stored haematopoietic cells (e.g. haematopoietic stem cells or granulocyte precursor cells obtainable therefrom), and granulocytes (e.g. neutrophils) differentiated therefrom are matched to cancer patients based on their cancer type, blood type (ABO, rhesus and HLA), and/or genetics. Patients may also be matched based on human leukocyte antigen (HLA) similarity.
Patients are treated using:
-
- IV infusion of haematopoietic cells (including haematopoietic stem cells, and granulocyte precursor cells) together with granulocyte-colony stimulating factor, human growth hormone, serotonin, and interleukin into the patient; or
- IV infusion of stimulated granulocyte precursor cells (obtainable from haematopoietic stem cells) into the patient. Without wishing to be bound by theory, it is believed that said cells naturally differentiate into granulocytes (e.g. neutrophils) having a high CKA in a CKA assay in vivo; or
- direct IV infusion of granulocytes (e.g. neutrophils) having a high CKA in a CKA assay which have been differentiated from haematopoietic cells (e.g. haematopoietic stem cells).
Typically, cells are infused once weekly for 8 weeks with a cell volume of 2×1011 administered per week. Progress of the therapy is monitored and dosing is adapted accordingly.
DNA genotypes from human RNA-seq data were ascertained via the SAMtools mpileup function as done previously21 (link). Human genotypes derived from RNA-seq data were phased and imputed with Beagle version 5.1, which uses a probabilistic Hidden Markov Chain model that performs well for sequencing data with sparse genomic coverage22 (link). We would like to caution the reader that Beagle was originally developed for genome-wide DNA variant data and not RNA-sequencing data. Our analyses used a few methods and criteria for quality control (QC) including: genotyping rate > 95%, minor allele frequency > 0.10, Hardy–Weinberg equilibrium > 1e-6, > 5 reads per sample, Phred Score > 20 and an imputation score > 0.3. The input for imputation was 40,878 called genotypes that were common among all samples and passed initial QC. These variants were imputed to 1000 Genomes Phase III all data, which resulted in 570,755 SNPs, 178,598 of which passed QC. These ~ 170 k variants were used for polygenic score and sQTL analyses. Note, that the 91.9% of these SNPs were present in the AUD GWAS, but that GWAS has 77.9 times more SNPs than the current study. Thus, we encourage the reader to use caution in interpreting our polygenic score and sQTL analyses given the limited number of individuals and the number of SNPs used.
Two cohorts of vaccinated NHPs received a booster immunization after randomizing each group within a cohort based on their baseline characteristics (Fig.
In the mRNA-primed cohort, six adult male and six adult female Mauritius cynomolgus macaques (Macaca fascicularis) aged 4–10 years, selected based on their responses to the primary vaccination, were randomly allocated to three groups of four animals according to their baseline characteristics.
In the subunit-primed cohort, 15 adult male Indian rhesus macaques (Macaca mulatta) aged 4–7 years were randomly allocated to three groups of five animals. In the priming phase, animals received two immunizations of either Sanofi’s mRNA COVID (ancestral D614) experimental candidate vaccines or CoV2 preS dTM-AS03 (ancestral D614) vaccine through the intramuscular route in the deltoid at day 0 and day 21. Seven months after the primary immunization, both cohorts were immunized with CoV2 preS dTM (ancestral)–AS03, CoV2 preS dTM (Beta)–AS03, and a bivalent CoV2 preS dTM (ancestral + Beta)–AS03. All groups received a total dose of 5 µg of CoV2 preS dTM antigen. All immunologic analyses were performed blinded on serum collected at 7, 14, 21, 28, 56, 84 days, and 6 months post-boost injection for D614G and Beta seroneutralizations; on D14, 56, 84, and 6 months for Delta; on D14 and 6 months for Omicron (BA.1), Omicron BA.4/5, and SARS-CoV1. Animal studies were conducted in compliance with all relevant local, state, and federal regulations, and were approved by the New Iberia Research Center.